Stockscreener 앱 받기
6.68
1.83%
0.12
시장 영업 전:
6.69
0.01
+0.15%
Kazia Therapeutics Limited Adr 주식(KZIA)의 최신 뉴스
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.66% _newTouch_By Investing.com - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.66% - Investing.com
Kazia Therapeutics (KZIA) resale filing details $46.5M cash boost and runway to 2028 - Stock Titan
Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance - The Globe and Mail
Kazia Therapeutics secures $46.5 million through private placement to address Nasdaq compliance - MSN
Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance - The Globe and Mail
Kazia Therapeutics (NASDAQ: KZIA) closes $46.5M private placement amid Nasdaq review - Stock Titan
You might want to take a look at Kazia Therapeutics Limited ADR (KZIA) now - setenews.com
Kazia Therapeutics (NASDAQ: KZIA) expects $46.5M net from PIPE to extend cash runway - Stock Titan
Check out these key findings about Hub Cyber Security Ltd (HUBC) - setenews.com
What is Kazia Therapeutics Limited ADR (KZIA) Stock Return on Shareholders’ Capital? - Setenews
Kazia Therapeutics Limited (KZIA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kazia Therapeutics reports immune complete response in TNBC - MSN
KZIA Shares Surge: Can This Momentum Last? - StocksToTrade
Kazia Therapeutics (KZIA) Stock Soars on Breakthrough Results in Breast Cancer Treatment - parameter.io
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing By Investing.com - Investing.com India
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing - Investing.com
Kazia Therapeutics Achieves Initial iCR… - digitalmore.co
Kazia reports immune-complete response in metastatic breast cancer By Investing.com - Investing.com South Africa
Kazia reports immune-complete response in metastatic breast cancer - Investing.com
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - The Manila Times
Kazia stock soars after patient shows complete response in TNBC trial - Investing.com Nigeria
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Kazia (Nasdaq: KZIA) reports iCR in metastatic TNBC and outlines Q4 oncology pipeline - Stock Titan
[6-K] KAZIA THERAPEUTICS LTD Current Report (Foreign Issuer) | KZIA SEC FilingForm 6-K - Stock Titan
[20-F] KAZIA THERAPEUTICS LTD Files Annual Report (Foreign Issuer) | KZIA SEC FilingForm 20-F - Stock Titan
How Does Wall Street Rate Shares Of DoubleDown Interactive Co Ltd ADR (DDI)? - fostersleader.com
Is Buying Stock In MediWound Ltd (MDWD) A Good Move Today? - fostersleader.com
Kazia Therapeutics stock seeks FDA guidance on paxalisib approval path - Investing.com
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - Benzinga
Kazia (NASDAQ: KZIA) to request FDA Type C on GBM OS; NDA path under review - Stock Titan
A Look at HighPeak Energy Inc (HPK) Shares in the Recent Past Indicates Growth - Setenews
Kazia (KZIA) secures PD-L1 degrader NDL2 with $1.39M payment - Stock Titan
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - Stock Titan
KZIA Stock Institutional Owners - Quiver Quantitative
Kazia reports 86% tumor reduction in expanded access case - Investing.com India
86% Tumor Reduction: Kazia's Experimental Cancer Drug Paxalisib Shows Dramatic Results in TNBC Patient Study - Stock Titan
Revolutionary AI Platform to Combat 25% of Childhood Brain Cancer Deaths: Kazia's New Research Initiative - Stock Titan
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG - Ariva
Kazia Therapeutics Achieves Breakthrough in Breast Cancer Treatment with Paxalisib - The Globe and Mail
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy - The Manila Times
100% Cancer Cell Cluster Elimination: Kazia's Breakthrough Drug Shows Perfect Score in Advanced Breast Cancer - Stock Titan
Leptomeningeal Metastases Market to Exhibit Growth at a - GlobeNewswire
Novogen Limited (NASDAQ:KZIA) Sees Large Growth in Short Interest - Defense World
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market - The Manila Times
Kazia Therapeutics raises US$2m via discounted private placement to fund trials | KZIA SEC FilingForm 6-K - Stock Titan
Kazia Therapeutics Announces At the Market Offering Agreement - The Globe and Mail
Kazia Therapeutics starts US$1.9M ATM ADS program; CEO exits board | KZIA SEC FilingForm 6-K - Stock Titan
Glioblastoma Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - Barchart.com
28.63%
자본화:
|
볼륨(24시간):